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ABSTRACT
Cholangiocarcinoma is an aggressive, strongly chemoresistant liver malignancy.
Leukemia inhibitory factor (LIF), an IL-6 family cytokine, promotes progression of 
various carcinomas. To investigate the role of LIF in cholangiocarcinoma, we evaluated 
the expression of LIF and its receptor (LIFR) in human samples. LIF secretion and 
LIFR expression were assessed in established and primary human cholangiocarcinoma 
cell lines. In cholangiocarcinoma cells, we tested LIF effects on proliferation, invasion, 
stem cell-like phenotype, chemotherapy-induced apoptosis (gemcitabine+cisplatin), 
expression levels of pro-apoptotic (Bax) and anti-apoptotic (Mcl-1) proteins, with/
without PI3K inhibition, and of pSTAT3, pERK1/2, pAKT. LIF effect on chemotherapy-
induced apoptosis was evaluated after LIFR silencing and Mcl-1 inactivation.
Results show that LIF and LIFR expression were higher in neoplastic than in 
control cholangiocytes; LIF was also expressed by tumor stromal cells. LIF had no 
effects on cholangiocarcinoma cell proliferation, invasion, and stemness signatures, 
whilst it counteracted drug-induced apoptosis. Upon LIF stimulation, decreased 
apoptosis was associated with Mcl-1 and pAKT up-regulation and abolished by PI3K 
inhibition. LIFR silencing and Mcl-1 blockade restored drug-induced apoptosis.
In conclusion, autocrine and paracrine LIF signaling promote chemoresistance 
in cholangiocarcinoma by up-regulating Mcl-1 via a novel STAT3- and MAPK-
independent, PI3K/AKT-dependent pathway. Targeting LIF signaling may increase 
CCA responsiveness to chemotherapy.
INTRODUCTION
Cholangiocarcinoma (CCA) is a highly aggressive 
cancer arising from epithelial cells lining intrahepatic (iCCA) 
or extrahepatic (eCCA) bile ducts. Although considered 
a rare tumor, incidence of CCA (particularly iCCA) has 
steadily increased over the last few decades [1]. Despite this 
trend, treatment options remain limited to surgical resection 
and liver transplantation, and the overall survival beyond 
a year from diagnosis still remains less than 5% [1, 2]. In 
fact, resection can only be offered to a minority of patients 
(20–40%) because of a propensity for early intrahepatic 
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or lymph node metastatic dissemination, whereas liver 
transplant is available only for carefully selected cases in a 
few, highly-specialized liver centers [2, 3]. Both procedures 
are further complicated by high rates of recurrence [2, 
3]. For patients ineligible for surgery, palliation including 
radiotherapy, photodynamic therapy or stenting to relieve 
biliary obstruction, may provide some benefit [2, 4]. Notably, 
chemotherapy is recognized as largely ineffective due to the 
high resistance of CCA cells to drug cytotoxicity [5]. A recent 
study shows that combined administration of gemcitabine 
(GEM) and cisplatin (CDDP) in the treatment of advanced 
CCA increases patient overall survival [6] of about four 
months compared with patients treated with GEM alone [6].
Mechanisms of chemoresistance in CCA are poorly 
understood but the extensive desmoplastic reaction typical 
of CCA has been suggested to play a role. In fact, the close 
interplay between the cancer and surrounding stromal 
cells, i.e. cancer-associated fibroblasts (CAF) and tumor-
associated macrophages (TAM), may be responsible for 
providing cancer cells with several pro-invasive functions, 
including proliferation, invasion, migration and resistance 
to apoptosis [7, 8]. Among the cytokines released within 
the tumor microenvironment, interleukin (IL)-6 plays a 
pivotal role in CCA pathogenesis, as a potent stimulator 
of cancer growth and progression [9, 10].
Leukemia inhibitory factor (LIF) is a pleiotropic 
pro-inflammatory cytokine belonging to the IL-6 
superfamily secreted by a variety of cells including 
epithelial and stromal cells (fibroblasts, monocytes, 
macrophages and T-cells), albeit generally at very low 
levels [11]. However, LIF secretion may be stimulated 
by pro-inflammatory cytokines, such as IL-6, IL-1 and 
tumor necrosis factor (TNF)-α, leading to elevated serum 
LIF levels in cancer patients [12, 13]. LIF effects on 
cell functions are multifaceted, but still not extensively 
detailed. They include differentiation and maintenance of 
pluripotency, proliferation and apoptosis, pro- and anti-
inflammatory stimuli, depending on the cell maturity 
and the cell type that the cytokine is acting upon [11, 13, 
14]. Following LIF binding, the low affinity LIF receptor 
(LIFR) dimerizes with the glycoprotein (gp) 130 subunit, 
to form a high-affinity complex which transduces the LIF 
signal through different intracellular pathways, including 
Janus kinase (JAK)-signal transducer and activator of 
transcription (STAT), mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) or 
phosphatidylinositol-3 kinase (PI3K) [15]. Increasing 
numbers of studies support LIF as an important player in 
tumorigenesis and metastatic spread in various epithelial 
cancers [16–19]. LIF and LIFR/gp130 were found to 
be expressed in most of 30 human carcinoma cell lines 
[20]. However, LIF effects were extremely variable, and 
often opposing, as it induced proliferation in breast and 
pancreatic carcinomas but apoptosis in colon and gastric 
carcinomas; these effects were strictly influenced by the 
signaling pathways activated [20].
To date, very little is known about the role of 
LIF in CCA. Therefore, in this study, we sought: 1) the 
distribution of LIF, LIFR, and gp130 in human CCA liver 
tissue derived from surgical resection; 2) the secretion of 
LIF and expression of LIFR in primary and established 
human CCA cell lines; 3) the functional effects of LIF 
on CCA cells with respect to: a) cell proliferation and 
invasion, b) cell viability and apoptosis in response to the 
chemotherapeutic agents currently used in CCA (GEM, 
CDDP), c) the induction of a stem cell-like phenotype; d) 
the expression of pro- and anti-apoptotic proteins; and e) 
the downstream effectors of the signal transduction.
RESULTS
LIF, LIFR and gp130 were extensively  
expressed by bile ducts in CCA compared to 
peritumoral tissue
Analysis of histological sections from resected 
human CCA liver revealed a significantly more 
extensive immunoreactivity of LIF (p < 0.001) and LIFR 
(p < 0.001) (Table 1) on bile ducts in tumoral areas (Figure 
1A, 1C) compared with matched, peritumoral tissue (Figure 
1B, 1D). Bile ducts of peritumoral areas were LIF-negative 
in all 12 samples, whilst 17/19 (89%) of neoplastic tissue 
contained LIF-positive bile ducts of different degree 
(Table 1). Similarly, the tumor reactive stroma surrounding 
the neoplastic bile ducts showed more extensive LIF 
immunoreactivity than the peribiliary stroma in peritumoral 
tissue (p < 0.001) (Table 1). Immunofluorescence studies 
revealed, more specifically, that in the tumor reactive 
stroma, LIF was expressed by inflammatory cells (CD45 
positive), likely including macrophages, lymphocytes 
and neutrophils as evaluated by immunoperoxidase, 
and CAF (α-smooth muscle actin (α-SMA) positive) 
(Figure 1G, 1H). Only 4/12 peritumoral samples (33%) had 
extensive (>30%) LIFR staining in bile ducts, however, 
extensive LIFR positivity in neoplastic bile ducts was 
present in 17/19 (89%) CCA samples (Table 1). Gp130 
expression on bile ducts in CCA and peritumoral tissue 
paralleled that of LIFR (Figure 1E, 1F). By categorizing 
the CCA areas, a significantly higher extent of LIF staining 
in ‘ductular-like’ than in ‘mucin-producing’ tumoral bile 
ducts was determined (Supplementary Figure  1A, 1C); 
in contrast, no significant differences in the extent of 
LIFR staining were found between the two CCA subtypes 
(Supplementary Figure  1B, 1C).
LIFR protein expression was greater in 
CCA than controls
Relative amounts of LIFR protein obtained from 
primary and established CCA cell lines, and control 
cholangiocytes were evaluated by Western blotting 
(WB). Although LIFR protein expression levels were 
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heterogeneous amongst CCA cholangiocytes, the average 
level was 7 times greater than that of the control (1.05 ± 
0.56 vs. 0.14 ± 0.03) (Figure 2A).
LIF secretion by cholangiocytes was variable
Using ELISA, no significant difference was 
found between the amount of LIF secreted by primary 
cholangiocytes from CCA and controls (29.9 ± 28.7 vs. 
20.7 ± 0.3 pg/mL). However, the amount of LIF secreted 
by primary CCA cholangiocytes was extremely variable, 
ranging from 0 to 95.7 pg/mL (Figure 2B). Amongst the 
established CCA cell lines, HuCCT-1 (iCCA) and TFK-
1 (eCCA) expressed LIFR and secreted LIF (Figure 
2A, 2B), as confirmed by immunofluorescence in cultured 
cells (Figure 2C, 2D), therefore these cell lines were 
selected for subsequent in vitro experiments.
Data on LIFR expression and LIF secretion 
(obtained by WB analysis and ELISA respectively) were 
further confirmed by real-time PCR in established and 
primary CCA cell lines as well as in control cholangiocytes 
(Supplementary Figure  2A, 2B).
LIF did not induce proliferation and  
invasion of established CCA cell lines, whilst 
it protected from apoptosis induced by 
chemotherapeutic agents
HuCCT-1 and TFK-1 cells challenged with increasing 
doses of recombinant human (rh) LIF did not show any 
significant increase in the proliferative rate, except for 
a minimal change with the lowest dose in TFK-1 cells 
(Supplementary Figure  4A, 4B). Additionally, no change 
in invasive functions was observed with both CCA cell 
lines in response to LIF (Supplementary Figure  4E, 4F). To 
understand whether lack of LIF’s proliferating effects was 
affected by autocrine LIF production by CCA cells, possibly 
inducing a constitutive activation of cell proliferation which 
precludes further activation upon ligand stimulation, we 
evaluated MTS assay in CCA cells with genetic inactivation 
of LIFR. The quality of the reduction in LIFR expression in 
HuCCT-1 and TFK-1 cells was evaluated by both real-time 
PCR and WB using 3 different siRNAs (Supplementary 
Figure 3). Using the 2 most effective siRNAs (siRNA1 and 
siRNA2), LIF’s effects on cell proliferation were evaluated 
by comparing silenced cells with scrambled controls in 
absence of rhLIF stimulation. No MTS decrease was 
found in LIFR silenced cells compared with scrambled 
controls (Supplementary Figure 4C, 4D). We next turned 
at evaluating whether LIF can protect CCA cells from 
the cytotoxic effects of chemotherapeutic drugs currently 
used in the treatment of CCA. HuCCT-1 and TFK-1 cells 
were treated with CDDP, GEM, and GEM+CDDP after 
a pre-incubation with/without LIF, and their viability 
assessed by MTS. A drug-induced decrease in cell viability 
by 34–89% and 23–64% was observed in HuCCT-1 and 
TFK-1 cells, respectively (Table 2). This cytotoxic effect 
was significantly counteracted by rhLIF, which augmented 
cell viability by up to 69.0 ± 36.7% in HuCCT-1 (Figure 
3A) and 73.1 ± 17.7% in TFK-1 (Figure 3B) cells. To 
Table 1: Extent of LIF and LIFR-positive bile ducts/stromal cells in CCA and peritumoural areas of 
resected liver tissue sections (0 = <5%; 1 = 5–30%; 2 = 30–70%; 3 = >70% area of positive ducts) 
LIF
BILE DUCTS STROMAL CELLS
Score CCA Peritumoral CCA Peritumoral
0 2 12 1 7
1 7 0 8 4
2 9 0 8 1
3 1 0 2 0
Total 19 12 19 12
LIFR
BILE DUCTS
Score CCA Peritumoral
0 1 2
1 1 6
2 5 3
3 12 1
Total 19 12
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understand whether cytoprotection was related to anti-
apoptotic mechanisms promoted by LIF, we assessed 
active caspases 3/7. Up-regulation of these caspases is 
the hallmark of an apoptotic response and is observed in 
CCA cell lines exposed to GEM+CDDP. The pre-treatment 
with rhLIF significantly reduced caspases 3/7 activity 
by 24% in HuCCT-1 and 22% in TFK-1 cells compared 
to cells challenged with GEM+CDDP in absence of LIF 
pre-treatment (Figure 3C, 3D). LIF’s ability to exert 
cytoprotective effects in CCA was confirmed in cells 
silenced for LIFR. Following treatment with GEM+CDDP, 
genetic inactivation of LIFR in cells exposed to rhLIF 
led to an increased activation of caspases 3/7 of an extent 
comparable to scrambled cells and to cells without rhLIF 
pre-treatment (Figure 3C, 3D).
LIF did not induce a stem cell-like phenotype in 
established CCA cell lines
To evaluate whether the protective potential of LIF 
against apoptosis was associated with a dedifferentiation of 
CCA cells to a stem cell-like phenotype, as described for LIF 
in malignant melanoma [17], we studied the gene expression 
of stem cell markers, Nanog and Oct4, following LIF 
Figure 1: LIF, LIFR and gp130 immunohistochemical expression in CCA and peritumoral areas of human liver 
samples. In CCA bile ducts, the extensiveness of LIF A. expression was heterogeneously distributed amongst samples, whilst the staining 
of LIFR C. and gp130 E. was more homogeneous. In contrast, LIF B., LIFR D. and gp130 F. immunoreactivity was significantly less in bile 
ducts of matched peritumoral tissues. By immunohistochemistry and dual immunofluorescence we demonstrate that LIF (green) was also 
extensively expressed by CD45+ inflammatory cells (red, G.) and α-SMA+ cells (CAF, red, H.) that juxtaposed neoplastic biliary structures 
(A, black arrows and inset, G, and H) (Original magnification: A-H, 200 ×; insets, 400 ×).
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stimulation. However, no significant up-regulation of either 
stem cell marker was detected in LIF-treated compared to 
untreated cells (Supplementary Figure  5A, 5B).
LIF-induced Mcl-1 up-regulation is mediated by 
PI3K/Akt, but neither by STAT3 nor ERK1/2 
activation, in CCA cells
To dissect the intracellular signaling that mediates 
the protective effect of LIF against drug-induced apoptosis 
in CCA cells, relative expression levels of pBax (pro-
apoptotic protein), and Bcl-2 and Mcl-1 (anti-apoptotic 
proteins) were studied by WB in LIF pre-treated HuCCT-1 
and TFK-1 cells. Compared with untreated cells, pBax 
levels remained unchanged (Supplementary Figure 
6A, 6B), whilst Mcl-1 levels increased significantly in 
both CCA cell lines (Figure 4A, 4B). In contrast with pBax 
and Mcl-1, Bcl-2 was not expressed in either HuCCT-1 
or TFK-1 cells (data not shown). LIF did not induce 
any significant changes in the phosphorylation levels of 
STAT3 (Figure 5A, 5B), an effector classically activated 
by LIF [21], or of ERK1/2 (Figure 5C, 5D) in either CCA 
cell line. In contrast, LIF stimulated the phosphorylation 
of AKT (Figure 5E, 5F). The modulatory effect of the 
PI3K/AKT pathway on LIF-induced Mcl-1 up-regulation 
was confirmed by treating CCA cells with LY294002, a 
specific PI3K inhibitor, which significantly reduced Mcl-1 
expression in LIF-stimulated HuCCT-1 and TFK-1 cells 
(Figure 4C, 4D).
Mcl-1 inactivation prevented LIF cytoprotective 
effects from chemotherapy-induced apoptosis 
in CCA cells
To demonstrate that Mcl-1 plays a central role in 
the LIF-dependent protection of CCA cells from the 
cytotoxic effects of chemotherapeutic drugs, we evaluated 
drug-induced apoptosis in HuCCT-1 and TFK-1 cells 
treated with the selective Mcl-1 inhibitor UMI-77. At 
our given dosage (10 μM) [22], UMI-77 did not induce 
any change in cell viability (data not shown), nor affect 
Mcl-1 expression in both cell lines (data not shown). By 
Figure 2: LIFR and LIF expression in human primary and established CCA cell lines. By WB, LIFR protein levels were 
higher although variable in primary (n = 7) and established (n = 3) CCA cell lines compared with control (n = 2) cholangiocytes A. Using 
ELISA, LIF was found to be secreted by both neoplastic and control cholangiocytes, however with a large variability B. Of the established 
CCA cell lines, only HuCCT-1 and TFK-1 cells expressed LIFR C. and LIF D., as shown by immunocytochemistry, which were then 
selected for in vitro experiments (Original magnification: 200x; *p < 0.05 vs. primary controls).
Table 2. Percentage of viable CCA cells following a 24-hour treatment with chemotherapeutic 
drugs normalized to untreated cells (MTS assay)
GEM (30 µM) CDDP (17 µM) Mix
HuCCT-1 38.32 ± 2.40 65.66 ± 4.10 10.87 ± 1.07
TFK-1 62.03 ± 7.21 77.16 ± 4.54 35.79 ± 5.36
GEM, gemcitabine; CDDP, cisplatin; Mix, GEM + CDDP
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caspase 3/7 activation assay, apoptosis of GEM+CDDP-
treated cells exposed to UMI-77 and LIF was comparable 
to GEM+CDDP-treated cells without LIF (Figure 4C, 4D). 
Together, these data point towards an Mcl-1-mediated 
anti-apoptotic effect of LIF against chemotherapeutic drug 
toxicity in CCA, which occurs in a PI3K/AKT-dependent, 
STAT3- and MAPK-independent manner.
DISCUSSION
In this study we investigated the role of LIF in 
CCA, a malignancy with extremely poor prognosis, with 
a view to unveiling molecular mechanisms responsible 
for its peculiar aggressiveness, and that may be amenable 
of therapeutic intervention. We demonstrate that in 
CCA: 1) LIF is expressed both in the bile ducts, 
particularly in the ‘ductular-like’ rather than ‘mucin-
producing’ subtype, and the stromal cell compartment, 
including CAF and TAM; 2) its cognate receptor LIFR is 
selectively up-regulated in neoplastic cholangiocytes; 3) 
LIF primarily aids tumoral cholangiocytes to resist 
apoptosis induced by the chemotherapeutic agents 
GEM and CDDP, without affecting cell proliferation, 
invasion or the gain of stemness signatures; 4) anti-
apoptotic mechanisms are mediated by Mcl-1, through 
activation of the PI3K/AKT pathway without involving 
the conventional LIF downstream effector STAT3 or 
MAPK/ERK; 5) in vitro inactivation of Mcl-1 prevents 
cytoprotective effects exerted by LIF from GEM+CDDP-
induced apoptosis in CCA cells.
In CCA, both cholangiocytes and stromal cells 
(CAF and inflammatory cells) are a source of LIF; 
conversely, LIF was not expressed by bile ducts in the 
peritumoral regions. In tumoral epithelia, LIF expression 
was heterogeneous, with a greater extensiveness in areas 
of a ductular phenotype. These findings are consistent with 
a recent study showing that LIF is overexpressed in CCA 
in conjunction with Oncostatin M, another IL-6 family 
cytokine that is closely related to LIF, with pleiotropic 
functions in cell differentiation, proliferation and invasion 
[23]. In culture conditions, we could confirm that LIF 
was variably secreted by CCA cells, in keeping with 
the heterogeneous distribution observed in histological 
specimens. LIF production by tumor cells directly 
correlates with a more invasive phenotype [24].
LIF secretion may be induced by several pro-
inflammatory cytokines, such as TNF-α, IL-6, IL-1β and 
TGF-β, variably released by macrophages and activated 
T-cells populating the local inflammatory microenvironment 
[12, 13, 25], as well as by the hypoxic conditions typically 
Figure 3: Protective effects of rhLIF on cell viability and apoptosis of CCA cells challenged with chemotherapeutic 
agents (GEM, CDDP, or GEM+CDDP). As evaluated by MTS assay, the pre-treatment of HuCCT-1 A. and TFK-1 B. cells with 
rhLIF was able to significantly counteract the cytotoxic effect of the chemotherapeutic agents, GEM, CDDP and GEM+CDDP (Mix). By 
caspase GLO 3/7 assay, the activation of caspases 3/7 in response to Mix in both CCA cell lines (C, D pale gray columns) was significantly 
reduced by the pre-treatment with rhLIF (100 ng/mL) (C, D black columns). Notably, the reduction in LIFR expression by two specific 
siRNAs was able to abolish the cytoprotective effects of rhLIF (C, D dark gray columns) (*p < 0.05 vs. untreated; ^p < 0.01 vs. untreated; 
°p < 0.05 vs Mix treatment; §p < 0.05 vs Scr treated with Mix; n = minimum of 3 in duplicate).
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featured in CCA [17]. Once secreted, LIF itself may induce 
the expression of LIFR by malignant cells, thus stimulating 
a positive loop [12, 17]. Our immunohistochemical, WB 
and real-time PCR data show that LIFR was selectively up-
regulated in CCA bile ducts. Transduction of LIF signaling 
occurs through its binding to the LIF receptor complex 
consisting of LIFR and the glycoprotein gp130. As opposed 
to LIFR, every cell type within the human body can express 
gp130 [26]. Nevertheless, we verified the expression 
of gp130 and found that it displayed a profile similar to 
LIFR, thereby indicating that LIF signaling is functionally 
active in tumoral cholangiocytes. Therefore, the de novo 
expression of LIF and the up-regulation of LIFR in CCA 
bile ducts, along with LIF overexpression in the tumor 
reactive stroma, indicate the presence of autocrine and 
paracrine LIF-mediated mechanisms in CCA. Znoyko 
et al. also suggested that an autocrine LIF/LIFR axis is 
active in reactive ductules of cirrhotic livers based on their 
intense neoexpression compared with bile ducts in normal 
liver, likely acting as an important signal for ductular 
reaction [27]. It is interesting to note that in our CCA 
series, LIF expression was more prevalent in the tumoral 
areas characterized by a ‘ductular-like’ appearance than by 
a ‘mucin-producing’ phenotype. These two specific iCCA 
phenotypes have been recently proposed to originate from 
topographically distinct cholangiocyte subpopulations, 
the major hilar ducts for the ‘mucin-producing’ form, 
and the smaller ducts associated with hepatic progenitor 
cells for the ‘ductular-like’ variant [28]. Further studies 
are warranted to understand whether LIF expression may 
indeed represent a signature of an iCCA subtype arising 
from hepatic progenitor cells.
Despite the observation that LIF was prevalently 
expressed in the ‘ductular-like’ areas of CCA, we found 
that LIF did not exert any proliferative or pro-invasive 
effects in tumoral cholangiocytes. LIF’s effects on 
neoplastic cells are highly variable, and its failure to 
stimulate proliferation or invasiveness has also been 
reported in other epithelial cancers [20]. The nature of the 
functional effect of LIF in different cancer cell types are 
dependent upon the signal transduction pathways that may 
be activated downstream of the receptor [11].
Our data illustrate that LIF enabled CCA cells to 
resist the pro-apoptotic effects induced by chemotherapeutic 
agents, such as GEM and CDDP, recently proposed in 
the treatment of advanced CCA [6]. In CCA cells that 
were exposed to GEM+CDDP treatment, LIF was able to 
increase their viability by up to 73% compared with the 
LIF-untreated cells. In accordance with these findings, 
LIF was able to hamper the increase of active caspases 
Figure 4: rhLIF’s regulation of the anti-apoptotic protein Mcl-1, and caspases 3/7 activity via Mcl-1, in CCA cells. By 
WB, rhLIF induced a significant up-regulation of Mcl-1 (anti-apoptotic) (A, B. black columns), in both HuCCT-1 A. and TFK-1 B. cells 
compared with untreated cells; this effect was abrogated by the specific PI3K inhibitor, LY294002 (A, B gray columns). Representative 
blots are shown below each respective graph. Interestingly, the protective effect of rhLIF pre-treatment from GEM+CDDP (Mix) 
cytotoxicity (C, D. black columns) was abolished by UMI-77, a selective, small molecule inhibitor of Mcl-1 (C, D dark gray columns) (*p 
< 0.05 vs. untreated; ^p < 0.01 vs. untreated; •p < 0.01 vs. LIF 10 without LY294002; °p < 0.05 vs. LIF 100; §p < 0.05 vs Mix treatment; 
§§p < 0.01 vs Mix treatment; n = minimum of 3).
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3/7 induced by GEM+CDDP by 22–24% in both CCA 
cells, a fundamental step initiating the cascade of events 
ultimately leading to apoptosis. Relevance of LIF signaling 
in conferring anti-apoptotic properties to CCA cells 
was confirmed by the restoration of cytotoxicity from 
GEM+CDDP when LIFR was silenced.
To study the mechanisms of resistance to drug-
induced apoptosis mediated by LIF, we first evaluated 
the possible involvement of LIF in inducing a stem cell-
like phenotype in CCA cells. Cancer stem cells have an 
unlimited capacity for self-renewal and a high capacity 
for drug resistance, and therefore their activation in CCA 
may explain the failure of current chemotherapies. LIF 
was recently reported for regulating stemness transcription 
factors, including Nanog and Oct4, in malignant melanoma 
[17]. Furthermore, Nanog and Oct4 are recognized as 
signatures of a stem cell-like phenotype in multiple types 
of human cancer as well as molecular players of resistance 
to gemcitabine or cisplatin treatment [29, 30]. However, in 
our experimental conditions, LIF failed to influence their 
gene expression levels, meaning the anti-apoptotic effect of 
LIF is unlikely to be related to a dedifferentiation of CCA 
cells to a cancer stem cell phenotype. Therefore, we turned 
to study the balance between the pro-apoptotic and anti-
apoptotic proteins of the Bcl-2 family. The anti-apoptotic 
Bcl-2 family member Mcl-1 acts as a survival factor both in 
hematogenous and solid tumors, and is currently regarded 
as a major oncogene [31]; its presence has been reported 
in both normal and malignant cholangiocytes [32]. We 
demonstrated that Mcl-1 expression is further augmented 
by LIF treatment in CCA cells, whilst the pro-apoptotic 
pBax expression remained unchanged, suggesting that this 
dysregulation could be a pivotal mechanism responsible 
for the resistance to apoptosis induced by LIF. The JAK/
STAT3, MAPK/ERK or PI3K pathways are three effectors 
putatively activated by LIF signaling [15, 16, 33] and 
may be involved in the regulation of Mcl-1 expression in 
the IL-6-mediated resistance to apoptosis in CCA [9, 10, 
33]. Therefore, we first looked at the activation of STAT3 
and ERK1/2, classical signals downstream of LIF [11, 
33]. However, LIF was unable to alter the levels of either 
pSTAT3 or pERK1/2 in CCA cholangiocytes, in vitro. On 
Figure 5: rhLIF acts through a STAT3/ERK1/2-independent, AKT-dependent pathway. Whereas rhLIF did not modify 
the phosphorylation levels of STAT3 A. B., or ERK1/2 C. D. in either HuCCT-1 or TFK-1 cell lines by WB, it did induce a significant 
phosphorylation of AKT E. F. compared with untreated cells. Representative blots are shown below each respective graph (*p < 0.05 vs. 
untreated; n = minimum of 3).
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the other hand, LIF stimulation up-regulated pAKT in 
both CCA cell lines, while their treatment with LY294002, 
a specific PI3K inhibitor, reduced the LIF induced up-
regulation of Mcl-1. This demonstrates that the positive 
modulation of Mcl-1 in CCA cells is dependent upon 
PI3K/AKT activation, as reported in breast cancer [16], 
nasopharyngeal carcinoma [18] and rhabdomyosarcoma 
cells [34]. The chemoresistant effects of LIF have also been 
reported in colorectal cancer cells by negatively regulating 
the tumor-suppressor p53 through a STAT3-dependent 
pathway [35]. In our in vitro model, Mcl-1 inactivation 
by UMI-77 restored sensitivity of CCA cells challenged 
with LIF to chemotherapeutic agents. This finding is in 
accordance with recent data indicating that maritoclax, a 
similar selective inhibitor of Mcl-1 via stimulation of its 
proteosomal degradation, is able to potently enhance drug-
induced apoptosis exerted by the small-molecule Bcl-2 
inhibitor ABT-737 in melanoma cells [36].
Overall, our results indicate that LIF signaling 
in CCA is a mechanism that promotes cancer growth 
and progression. Whereas LIF does not affect cell 
proliferation or invasion of cancer cells, it protects 
malignant cholangiocytes from chemotherapy-induced 
apoptosis via a STAT3- and MAPK-independent, PI3K/
AKT-dependent Mcl-1 activation. The pro-oncogenic 
effects of LIF rely on its secretion by both the tumoral 
cells themselves and the adjacent reactive stromal cells 
acting on the LIFR aberrantly expressed by neoplastic 
bile ducts (Figure 6). In particular, the autocrine effect 
is prominent in the ‘ductular-like’ areas of iCCA. On 
the other hand, LIF-mediated paracrine effects highlight 
the treatment-resistant functions exerted by the tumor 
reactive stroma in epithelial cancers with abundant 
desmoplasia. Since our histological samples were 
obtained from patients undergoing surgical resection, 
and, in our center, chemotherapy is only reserved for 
those with advanced CCA (which generally do not 
perform histological evaluation), correlating LIF/
LIFR expression with clinical data was not possible in 
the present study. However, we demonstrated that the 
downstream effectors of LIF signaling may represent 
innovative molecular targets amenable to thera-
peutic modulation to increase CCA responsiveness to 
conventional chemotherapy.
Figure 6: The working model illustrating the molecular mechanisms underlying the chemotherapy-resisting effects of 
LIF in neoplastic cholangiocytes. In CCA, LIFR is up-regulated by cholangiocytes under the influence of LIF released by both the 
neoplastic cholangiocytes (autocrine loop) and the tumor reactive stromal cells, including CAF and TAM (paracrine loop). When LIFR 
dimerizes with gp130, LIF signaling is transduced through PI3K/AKT rather than the conventional STAT3 or MAPK/ERK pathways to 
increase levels of the anti-apoptotic protein Mcl-1, which confers resistance to the cytotoxic effects of chemotherapeutic agents by reducing 
activation of caspases 3/7.
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MATERIALS AND METHODS
Tissue samples
Formalin-fixed, paraffin-embedded sections of 
surgically resected CCA liver from 19 patients were 
included in the immunohistochemical study and compared 
with the corresponding peritumoral areas where available 
(n = 12). The patients were predominantly male (12/19), with 
a median age of 64 years (min 35; max 81), and 63% (12/19) 
were iCCA. CCA areas were then categorized as ‘ductular-
like’ or ‘mucin-producing’ according to Komuta [28].
Cell lines
Three established human CCA cell lines were used: 
EGI-1, TFK-1 (both eCCA, purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen, 
DSMZ, Germany), and HuCCT-1 (iCCA, from Health 
Science Research Resource Bank, HSRRB, Japan), along 
with primary biliary cell preparations obtained from 
surgically resected human iCCA liver samples (n = 7), 
as described [37]. Human cholangiocytes isolated from 
liver explants of alcoholic liver cirrhosis (n = 2) served 
as controls. All specimens were reviewed by the same 
dedicated pathologist (AF) to confirm diagnosis. Local 
regional ethical committee approval was obtained for 
tissue collection and cell preparations.
LIF, LIFR and gp130 expression in tissues
By immunohistochemistry we evaluated the 
expression of LIF, LIFR and gp130 in bile ducts 
and the stromal compartment in both neoplastic and 
matched peritumoral areas. Further details are provided 
in the supplementary online section. The extent of 
immunoreactivity was scored by two independent 
observers (SDM, MC) as: 0 = < 5%; 1 = 5–30%; 2 = 30–
70%; 3 = > 70% area of positive cells, as reported [38]. 
In selected tissue specimens, dual immunofluorescence 
for LIF and α-SMA (myofibroblast marker) or CD45 
(inflammatory cell marker) was performed to assess the 
specific contribution of the different stromal cell types to 
LIF production.
LIF and LIFR expression in cells
To evaluate conformity of immunohistochemical 
findings with in vitro data, LIF and LIFR expression 
were then assessed in cultured cholangiocytes by 
immunocytochemistry. Further details are provided in the 
supplementary online section. LIFR protein expression 
was also assessed by WB in both established and primary 
CCA cholangiocyte lines. See Supplementary Materials 
for details. Furthermore, gene expressions of LIF and 
LIFR on CCA cell lines were evaluated by real-time PCR 
(see Supplementary Materials).
LIF secretion by cultured cholangiocytes
The supernatants of CCA and control cholangiocytes 
cultured for 24 h at a density of 5 × 104 were evaluated for 
the presence of secreted LIF using an ELISA kit, according 
to the supplier’s instructions (Raybiotech, Milan). For each 
experiment a LIF standard curve was generated.
Cell proliferation
HuCCT-1 and TFK-1 cells were cultured at a density 
of 1 × 104 for 48 h with/without exposure to increasing 
doses (0.1, 1, 10, 100 ng/mL) of recombinant human LIF 
(rhLIF, R&DSystems). Proliferation activity was assessed 
by MTS assay according to the supplier's instructions 
(CellTiter 96 AQueous One Solution Cell Proliferation 
Assay, Promega).
Cell viability
MTS assay was also used to assess whether LIF (24 
h pre-treatment at 0.1, 1, 10, 100 ng/mL) affected viability 
of HuCCT-1 and TFK-1 cells in response to a 24 h 
treatment with cisplatin, 17 μM (CDDP; Sigma-Aldrich) 
[39] and gemcitabine, 30 μM (GEM; Sigma-Aldrich) [40], 
either alone or in combination (GEM+CDDP).
Stem cell-like phenotyping
Real-time PCR was used to assess LIF effects 
(100 ng/mL) on Nanog and Oct4 gene expression. RNA 
was isolated from cultured cells, as described [41]. Further 
details are available in the supplementary section.
Cell invasiveness
The invasiveness of HuCCT-1 and TFK-1 cells was 
assessed by Boyden chamber assay as described [42]. 
Methodology is detailed in the Supplementary Materials.
Downstream effectors of LIF signaling  
in CCA cells
After exposure of HuCCT-1 and TFK-1 cells to 
rhLIF (10, 100 ng/mL) for 15 mins (STAT3, pSTAT3, 
ERK1/2, pERK1/2, AKT, pAKT) or 24 h (Bax, pBax, 
Bcl-2 and Mcl-1), their expression levels were evaluated 
by WB (see Supplementary Materials). To unravel the 
pathway regulating Mcl-1, its protein expression was also 
measured in CCA cells treated with the PI3K chemical 
inhibitor, LY294002 (10 μM, Sigma) [43], for 10 mins, 
then with rhLIF plus inhibitor for 24 h.
Activation of caspases 3/7
HuCCT-1 and TFK-1 cells were seeded into a 96-
well plate at 1 × 104 per well with/without rhLIF (100 ng/
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mL) for 24 h followed by treatment with GEM+CDDP 
for 12 h. The luminescence-based solution Caspase-Glo 3/7 
(Promega) was then used to assess activation of caspases 
3/7. Luciferase reaction was evaluated using a microplate 
reader (BMG Labtech).
Mcl-1 inactivation
Apoptotic response following GEM+CDDP trea-
tment, assessed as described above (Activation of 
caspases 3/7), was also evaluated upon Mcl-1 inhibition 
in HuCCT-1 and TFK-1 cells. We used a novel, selective, 
small molecule inhibitor of Mcl-1, UMI-77 (10 μM), for 
24 h [22]. Antagonism of Mcl-1 function by UMI-77 does 
not depend on the down-regulation of this protein, but on 
the ability to block the heterodimerization of Mcl-1 with 
several members of the Bcl-2 family, including Bax, Bak 
and Noxa [22, 44]. Inhibitory effect of UMI-77 is related 
to its binding to the BH3-binding groove of Mcl-1.
Silencing of LIFR
Gene silencing was performed using commercially 
available siRNAs against LIFR, and scramble RNA was 
used as a control (Life Technologies). HuCCT-1 and TFK-
1 cell lines were transfected using Lipofectamine 2000 
transfection reagent (Life Technologies). Further details 
are provided in the supplementary section.
Statistical analyses
Results are shown as the mean ± standard deviation. 
Statistical comparisons were made using Student’s t-test. 
Statistical analyses were performed using SPSS 20.0 
software (IBM Corp.). A p value < 0.05 was considered 
significant.
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